Description
A vetted, searchable, sortable database of 300+ investors who are actively investing in regenerative medicine (RM) and advanced therapy (AT) companies right now.
For 48 hours, you can claim this database for only $79.
Regenerative medicine companies are defined as those involved with cell therapies, gene therapies, exosomes, tissue engineering, biomaterials, or other related therapies involving the use of human cells and tissues.
Gene therapy is the use of genetic material to change the expression of a gene product, while cell therapies utilize living cells to create either direct or indirect effects within the human body. Exosomes exert their effects by carrying cell-specific cargos which are selectively taken up by recipient cells. Likewise, there are technologies that can impact the health of tissues and organs through the use of biomaterials, tissue engineering, and 3D bioprinting.
To develop these novel regenerative medicine (RM) and advanced therapy (AT) products, investor capital is often needed to support these therapeutics from preclinical development through clinical trials, and ultimately, to commercialization.
Regenerative medicine industry investors include:
- Venture Capital Groups
- Private Equity Firms
- Hedge Funds
- Investment Firms
- Endowment Funds
- Family Offices
- Angel Investors (for example, Tony Robbins, Bill Maris, Peter Diamandis and others)
Database of Regenerative Medicine (RM) Investors
This database reveals the identity and investment behavior of over 300 investors who specialize in companies commercializing regenerative medicine (RM) and advanced therapy (AT) products.
This database has compiled over several years, using the regenerative medicine (RM) and advanced therapy (AT) industry relationships our leadership has developed since BioInformant was founded in 2006. As you can imagine, we regularly crowd-source feedback from BioInformant’s partners, clients, colleagues, and readership, as well as utilize translators as necessary.Â
The quality of this database would not be possible without the past 19+ years of following this industry and developing proprietary datasets (to which AI does not have access).
Best of all, you don’t have to worry about AI errors or inaccuracies. If you want immediate and actionable insights from a trusted, U.S. based provider that specializes exclusively in stem cell and cell therapy market insights, then this database is for you.
At an investment of only $79, you have to ask yourself, is it worth paying for AI credits just to get back a product that is likely inaccurate and incomplete? If not, claim a vetted, quality controlled required below that you can access immediately, with no wait times or frustation required.
This comprehensive global database includes the following in searchable, sortable format:
- Investor Identity (Individual or Company Name)
- Type of Investor
- Year Founded
- City/State
- Country
- Company Website
- Regenerative Medicine (RM) Companies Funded
- Description of the Investor
- Phone Number
- Email Address
Use this database if you plan to pursue:
- Seed rounds
- Venture or financing rounds
- Private placements
- Loans and convertible debt
- Any activity requiring external funding
It can also be used to strengthen your network by identifying the regenerative medicine (RM) industry’s most influential investors. Imagine being immediately informed about investor profiles and preferences, without having to conduct research or validate its accuracy.
If you are in the process of raising investor capital for your company, product candidate, or clinical trial, then this database is a must-have.
